Mounjaro 5 mg/0.5 mL pre-filled single-dose pen ( Japan Version) 2 dose per box

### **Mounjaro (Japan Version) – 5 mg/0.5 mL Pre-filled Single-dose Pen (2 Doses per Box)**

**Overview**:
**Mounjaro** (with the active ingredient **tirzepatide**) is an innovative medication designed to improve blood sugar control in adults with type 2 diabetes. It functions as a dual receptor agonist, targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The **5 mg/0.5 mL pre-filled pen** is a single-use injection that delivers the medication subcutaneously. The Japan-specific version follows local regulatory requirements, but the drug’s effectiveness remains the same as in other markets.

**Dosage**:
– **5 mg/0.5 mL** is typically used as an introductory dose for patients starting tirzepatide treatment. Patients may begin at this dosage to assess their tolerance and response before transitioning to higher doses (e.g., 7.5 mg or 10 mg) if needed.
– The packaging includes **2 pre-filled pens per box**, each containing a single dose of 5 mg of tirzepatide.

**Key Features**:
– **Dual Mechanism of Action**: Tirzepatide activates both GIP and GLP-1 receptors, helping to enhance insulin secretion, reduce glucagon levels, and slow gastric emptying. This dual action offers a more comprehensive approach to managing blood sugar compared to single-action GLP-1 agonists.
– **Once Weekly Injection**: Mounjaro is administered once a week, making it a convenient treatment option for patients. The pre-filled pen ensures accurate dosing with minimal steps.
– **User-friendly Pen**: The pen is designed for easy, subcutaneous injection, typically delivered in the abdomen, thigh, or upper arm. The pen comes pre-assembled, with no need for mixing or preparation.

**Indications**:
– **Type 2 Diabetes**: Mounjaro is prescribed to improve glycemic control in adults with type 2 diabetes, especially when combined with other treatments like metformin or insulin.
– **Weight Reduction**: As a secondary benefit, many patients may experience weight loss, which can help in managing comorbidities such as obesity.

**Usage and Administration**:
– **Frequency**: Mounjaro 5 mg is injected subcutaneously once per week, on the same day each week. The dose can be administered with or without food.
– **Adjustable Dose**: Starting with 5 mg allows healthcare providers to monitor patients for any side effects and adjust the dosage as needed. Depending on the patient’s progress, doses may increase to 7.5 mg or more.

**Storage**:
– **Before Use**: Store the pre-filled pens in a refrigerator (2°C to 8°C). Do not freeze the pens.
– **After Use**: Once the pen is in use, it can be stored at room temperature (below 30°C) for up to 21 days.

**Japan-specific Packaging**:
– **2 Doses per Box**: The Japan version of Mounjaro comes with two 5 mg pre-filled pens, providing a two-week supply.
– The packaging, labeling, and instructions are designed to meet Japanese regulatory requirements, although the product’s formulation and usage are consistent with global standards.

**Conclusion**:
Mounjaro (tirzepatide) 5 mg/0.5 mL pre-filled pen is an effective starting dose for managing type 2 diabetes. Its dual-action mechanism makes it a powerful tool for improving blood sugar control while offering the added benefit of potential weight loss. The pre-filled pens are easy to use, with a once-weekly dosing schedule, making it convenient for patients managing diabetes.